- Home
- ONB vs LEGN Comparison
ONB vs LEGN Comparison
Compare ONB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONB
- LEGN
- Stock Information
- Founded
- ONB 1834
- LEGN 2014
- Country
- ONB United States
- LEGN United States
- Employees
- ONB N/A
- LEGN N/A
- Industry
- ONB Major Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ONB Finance
- LEGN Health Care
- Exchange
- ONB Nasdaq
- LEGN Nasdaq
- Market Cap
- ONB 6.8B
- LEGN 7.0B
- IPO Year
- ONB N/A
- LEGN 2020
- Fundamental
- Price
- ONB $20.72
- LEGN $33.97
- Analyst Decision
- ONB Buy
- LEGN Strong Buy
- Analyst Count
- ONB 8
- LEGN 13
- Target Price
- ONB $26.38
- LEGN $79.42
- AVG Volume (30 Days)
- ONB 3.4M
- LEGN 1.6M
- Earning Date
- ONB 04-22-2025
- LEGN 05-12-2025
- Dividend Yield
- ONB 2.74%
- LEGN N/A
- EPS Growth
- ONB N/A
- LEGN N/A
- EPS
- ONB 1.72
- LEGN N/A
- Revenue
- ONB $1,795,802,000.00
- LEGN $627,241,000.00
- Revenue This Year
- ONB $39.08
- LEGN $66.92
- Revenue Next Year
- ONB $20.16
- LEGN $51.77
- P/E Ratio
- ONB $11.89
- LEGN N/A
- Revenue Growth
- ONB 3.29
- LEGN 119.97
- 52 Week Low
- ONB $15.60
- LEGN $29.27
- 52 Week High
- ONB $24.49
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- ONB 53.82
- LEGN 50.50
- Support Level
- ONB $18.83
- LEGN $31.68
- Resistance Level
- ONB $21.11
- LEGN $35.32
- Average True Range (ATR)
- ONB 1.10
- LEGN 1.65
- MACD
- ONB 0.27
- LEGN 0.34
- Stochastic Oscillator
- ONB 88.20
- LEGN 75.74
About ONB Old National Bancorp
Old National Bancorp with almost $10 billion in assets following its latest acquisition, Old National Bancorp is a financial services bank holding company headquartered in Indiana. Based in Evansville, Ind., Old National owns multiple financial services operations in Indiana, Illinois, and Kentucky. The company provides a group of similar community banking services, including such products and services as commercial, real estate, and consumer loans; deposits; and brokerage, trust, and investment advisory services.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.